[ad_1]
As reported by the National Agency for Drug Control, currently national authorities throughout Europe, including Lithuania, are canceling drugs containing valsartan manufactured by Zhejiang Huahai Pharmaceuticals in China.
The review began after the determination of the impurity by the manufacturer The active substance valsartane, which is provided by the company to manufacturers in the European Union, which produce certain drugs containing valsartan. The appearance of impurities in the active substance was unexpected and would be related to changes in the mode of production of the active substance.
Drugs containing valsartan are intended for hypertensive patients to reduce complications such as myocardial infarction and stroke. It is also intended for patients with heart failure or recent myocardial infarction
The European Medicines Agency will continue to badess whether impurities pose a risk to patients.
An unexpected impurity was found in the active substance used only in certain drugs.
You may receive another medicine containing valsartan or an alternative treatment when you seek prescription medical advice.
Medicines containing impurities are already withdrawn from the market, and drugs in pharmacies
You will find the list of medicines with valsartan removed from the Lithuanian market here
It is strictly forbidden to use the information published by DELFI on other sites, media or elsewhere, or distribute our material in any form whatsoever. without consent, and if the consent is g it is necessary to mention DELFI as a source.
[ad_2]
Source link
